Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated metastatic pancreatic cancer in…
Pancreatic cancer
Ideaya Biosciences and Roche announced a collaboration to test two experimental treatments for pancreatic cancer in combination. The companies will test Ideaya’s…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental delivery method for the chemotherapy oxaliplatin as a potential treatment…
Following “encouraging findings” from an early study, Can-Fite Biopharma is planning a clinical trial to test…
The U.S. Food and Drug Administration (FDA) has given Actuate Therapeutics the green light to begin a clinical trial testing an oral formulation of…
An artificial intelligence (AI) tool can detect early-stage pancreatic cancer on standard medical scans up to three years before a clinical diagnosis, according to…
Almost a third of people with advanced pancreatic cancer taking part in an ongoing clinical trial had stable disease following treatment with the experimental…
Akeso’s candidate therapy cadonilimab, in combination with chemotherapy, showed encouraging results as a first-line treatment for advanced pancreatic cancer in the Phase 2 COMPASSION-26 study. The…
Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial…
A new CAR T-cell therapy designed to treat gastric (stomach) and pancreatic cancers will soon be available to patients in China, according to Jiahui International…
